YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2

Abstract

Background: Parkinson's disease (PD) is a common neurodegenerative movement disorder, mainly characterized by the degeneration and loss of dopaminergic neurons in the substantia nigra. Oxidative stress is considered to be a key contributor to dopaminergic neuronal degeneration, triggering a series of downstream events such as mitochondrial dysfunction, neuroinflammation and misfolded protein aggregation, which ultimately exacerbate the development of PD. Deubiquitinating enzymes (DUBs) regulate oxidative stress, but their roles in PD remain unclear.

Methods: GEO database analysis and western blotting were used to analyze the expression of YOD1in PD patients and PD mouse models. Genetic knockout (KO) of YOD1 was performed to assess its effects in PD pathogenesis. The substance of YOD1 was measured via co-immunoprecipitation (Co-IP) coupled with LC-MS/MS analysis. Then the effect of YOD1-mediated motor deficits and oxidative damage were investigated using open field test, swimming test, pole test, immunofluorescence (IF) and cellular analyses.

Results: YOD1 was highly expressed in PD patients and 6-OHDA-induced PD model mice and mediated reactive oxygen species (ROS) production. YOD1 KO ameliorated motor impairments and oxidative stress in PD model mice. YOD1 directly bound PKM2 and reduces its ubiquitination level by removing the K63-linked ubiquitin chain of PKM2, thereby increasing the tetramer level and reducing the dimer level of PKM2. It then inhibited dimerized PKM2 entry into the nucleus and regulated Nrf2-mediated antioxidant responses, but YOD1 does not change the stability of PKM2 protein.

Conclusions: Our study identifies YOD1 as a oxidative-sensitive regulator of PD progression, operating via the YOD1-PKM2-Nrf2 axis. Targeting YOD1 may offer a novel therapeutic strategy for PD.

Keywords

oxidative stress / Parkinson's disease / PKM2 / YOD1

References

[1] Armstrong M, Okun M. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020; 323: 548-560.

[2] Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023; 8: 73.

[3] Chen F, Chen S, Si A, et al. The long-term trend of Parkinson's disease incidence and mortality in China and a Bayesian projection from 2020 to 2030. Front Aging Neurosci. 2022; 14: 973310.

[4] Borsche M, Pereira S, Klein C, Grünewald A. Mitochondria and Parkinson's disease: clinical, molecular, and translational aspects. J Parkinsons Dis. 2021; 11: 45-60.

[5] Misrani A, Tabassum S, Yang L. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease. Front Aging Neurosci. 2021; 13: 617588.

[6] Park J, Davis R, Sue C. Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018; 18: 21.

[7] Weng M, Xie X, Liu C, Lim KL, Zhang CW, Li L. The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson's disease. Parkinsons Dis. 2018; 2018: 9163040.

[8] Dias V, Junn E, Mouradian M. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013; 3: 461-491.

[9] Facecchia K, Fochesato L, Ray S, Stohs S, Pandey S. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol. 2011; 2011: 683728.

[10] Shao G. Dexmedetomidine inhibits cerebral nerve cell apoptosis after cerebral hemorrhage in rats via the Nrf2/HO-1/NQO1 signaling pathway. Eur Rev Med Pharmacol Sci. 2022; 26: 4574-4582.

[11] Chen Y, Qiu X. Ubiquitin at the crossroad of cell death and survival. Chin J Cancer. 2013; 32: 640-647.

[12] Wang Y, Wang F. Post-translational modifications of deubiquitinating enzymes: expanding the ubiquitin code. Front Pharmacol. 2021; 12: 685011.

[13] Xu Q, Liu M, Gu J, et al. Ubiquitin-specific protease 7 regulates myocardial ischemia/reperfusion injury by stabilizing Keap1. Cell Death Discov. 2022; 8: 291.

[14] Niederkorn M, Ishikawa C, M Hueneman K, et al. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36: 438-451.

[15] Oikawa D, Gi M, Kosako H, et al. OTUD1 deubiquitinase regulates NF-κB- and KEAP1-mediated inflammatory responses and reactive oxygen species-associated cell death pathways. Cell Death Dis. 2022; 13: 694.

[16] Pan J, Zhao J, Feng L, Xu X, He Z, Liang W. Inhibition of USP14 suppresses ROS-dependent ferroptosis and alleviates renal ischemia/reperfusion injury. Cell Biochem Biophys. 2023; 81: 87-96.

[17] Tanji K, Mori F, Miki Y, et al. YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity. Neurobiol Dis. 2018; 112: 14-23.

[18] Danial NN, Hockenbery DM. Chapter 18 - Cell death. In: Hoffman R, Benz EJ, Silberstein LE, eds. Hematology. 7th ed. Elsevier; 2018: 186-196.

[19] Liu C, Huang S, Wang X, et al. The Otubain YOD1 suppresses aggregation and activation of the signaling adaptor MAVS through Lys63-linked deubiquitination. J Immunol. 2019; 202: 2957-2970.

[20] Farkas A, Zsindely N, Nagy G, Kovács L, Deák P, Bodai L. The ubiquitin thioesterase YOD1 ameliorates mutant Huntingtin induced pathology in Drosophila. Sci Rep. 2023; 13: 21951.

[21] Lehmensiek V, Tan E, Liebau S, et al. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Neurochem Int. 2006; 48: 329-340.

[22] Cousineau J, Plateau V, Baufreton J, Le Bon-Jégo M. Dopaminergic modulation of primary motor cortex: from cellular and synaptic mechanisms underlying motor learning to cognitive symptoms in Parkinson's disease. Neurobiol Dis. 2022; 167: 105674.

[23] Weihe E, Depboylu C, Schütz B, Schäfer M, Eiden L. Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol Neurobiol. 2006; 26: 659-678.

[24] Daubner S, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2011; 508: 1-12.

[25] Subramaniam S, Chesselet M. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 2013; 106-107: 17-32.

[26] Wei Y, Lu M, Mei M, et al. Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nat Commun. 2020; 11: 941.

[27] Azoitei N, Becher A, Steinestel K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation. Mol Cancer. 2016; 15: 3.

[28] He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 2020; 21: 4777.

[29] Vomhof-Dekrey E, Picklo M. The Nrf2-antioxidant response element pathway: a target for regulating energy metabolism. J Nutr Biochem. 2012; 23: 1201-1206.

[30] Ohtake F, Saeki Y, Ishido S, Kanno J, Tanaka K. The K48-K63 branched ubiquitin chain regulates NF-κB signaling. Mol Cell. 2016; 64: 251-266.

[31] Swatek K, Komander D. Ubiquitin modifications. Cell Res. 2016; 26: 399-422.

[32] Yigang L, Dudu J, Lingjing J, et al. Mitochondrial dysfunction and Parkinson's disease. 2018.

[33] Trist B, Hare D, Double K. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019; 18: e13031.

[34] Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003; 53(Suppl 3): S26-S36. discussion S36-28.

[35] Puspita L, Chung S, Shim J. Oxidative stress and cellular pathologies in Parkinson's disease. Mol Brain. 2017; 10: 53.

[36] Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020; 5: 11.

[37] Zhong Q, Xiao X, Qiu Y, et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm (2020). 2023; 4: e261.

[38] Reyes-Turcu F, Ventii K, Wilkinson K. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009; 78: 363-397.

[39] Tsefou E, Walker AS, Clark EH, et al. Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches. Biochem J. 2021; 478: 4099-4118.

[40] Gao G, You L, Zhang J, Chang Y, Yu P. Brain iron metabolism, redox balance and neurological diseases. Antioxidants (Basel, Switzerland). 2023; 12: 1289.

[41] Zahra K, Dey T, Ashish , Mishra SP, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020; 10: 159.

[42] Yang W. Structural basis of PKM2 regulation. Protein Cell. 2015; 6: 238-240.

[43] Toller-Kawahisa JE, Hiroki CH, Silva CMDS, et al. The metabolic function of pyruvate kinase M2 regulates reactive oxygen species production and microbial killing by neutrophils. Nat Commun. 2023; 14: 4280.

[44] Zhao Y, Wang Y, Wu Y, et al. PKM2-mediated neuronal hyperglycolysis enhances the risk of Parkinson's disease in diabetic rats. J Pharm Anal. 2023; 13: 187-200.

[45] Jiang L, Gao Y, Wang G, Zhong J. Retracted Article: pKM2 overexpression protects against 6-hydroxydopamine-induced cell injury in the PC12 cell model of Parkinson's disease via regulation of the brahma-related gene 1/STAT3 pathway. RSC Adv. 2019; 9: 14834-14840.

[46] Liu Y, Zhang L, Zhao J, et al. Effective-component compatibility of Bufei Yishen Formula III suppresses mitochondrial oxidative damage in COPD: via Pkm2/Nrf2 pathway. Int J Chron Obstruct Pulmon Dis. 2024; 19: 1905-1920.

[47] Lv J, Ren Y, Tan Y, et al. Hernandezine acts as a CDK4 suppressor inhibiting tumor growth by the CDK4/PKM2/NRF2 axis in colon cancer. Phytomedicine. 2024; 131: 155775.

[48] Ding Z, Da HH, Osama A, Xi J, Hou Y, Fang J. Emodin ameliorates antioxidant capacity and exerts neuroprotective effect via PKM2-mediated Nrf2 transactivation. Food Chem Toxicol. 2022; 160: 112790.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.